Navidea biopharmaceuticals announces changes to board of directors composition

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on september 14, 2021, at a meeting of the board of directors (the “board”) of the company that followed the company's 2021 annual meeting of stockholders, s. kathryn rouan, ph.d. retired as chair of the board and as a director, and claudine bruck, ph.d. retired a
NAVB Ratings Summary
NAVB Quant Ranking